Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“In February 2007, we entered into an Agreement Concerning Glucokinase Activator Project with Novo Nordisk A/S (the "Novo License Agreement") whereby we obtained an exclusive, worldwide, sublicensable license under certain Novo Nordisk intellectual property rights to discover, develop, manufacture, have manufactured, use, and commercialize products for the prevention, treatment, control, mitigation, or palliation of human or animal diseases or conditions.”
FILING10-K0001641489-26-000010cik 0001641489
“Additionally, in conjunction with the CinRx Purchase Agreement the Company and CinRx entered into a Master Service Agreement whereby CinRx provides the Company with consulting, preclinical and clinical trial services, as enumerated in project proposals negotiated between the Company and CinRx from time to time.”
FILING10-K0001641489-26-000010cik 0001641489
“On February 28, 2024, we entered into a sales agreement (the "TD Cowen Sales Agreement") with Cowen and Company, LLC ("TD Cowen") pursuant to which we may offer and sell, from time to time, through or to TD Cowen, as sales agent or principal, shares of our Class A common stock having an aggregate offering price of up to $50.0 million, although we may only offer and sell under the TD Cowen ATM Offering up to one-third of the aggregate market value of our voting and non-voting common equity held by non-affiliates during any 12 calendar month period pursuant to General Instruction I.B.6 of Form S-3 .”
FILING10-K0001641489-26-000010cik 0001641489
“On June 22, 2021, vTv Therapeutics Inc. and Cantex Pharmaceuticals, Inc. ("Cantex") entered into a licensing agreement under which Cantex obtained exclusive worldwide rights to develop and commercialize azeliragon , vTv's novel antagonist of RAGE (the receptor for advanced glycation end products).”
FILING10-K0001641489-26-000010cik 0001641489
“Specifically, the Company will share various protocols with Cogna related to conducting the clinical trials and will provide the patient dosages and placebo of cadisegliatin needed to conduct the trials.”
FILING10-K0001641489-26-000010cik 0001641489
“Under the Second Amendment, Newsoara's rights in the Company's PDE4 inhibitor, HPP737 , will expand to include all countries of the world upon Newsoara's payment of the upfront fee of $20.0 million.”
FILING10-K0001641489-26-000010cik 0001641489
“The Company is the sponsor of this study that will be fully funded by G42 Investments.”
FILING10-K0001641489-26-000010cik 0001641489
“Revenue for the year ended December 31, 2024, includes a $1.0 million increase to the transaction price for the license performance obligation under the Newsoara License Agreement due to the satisfaction of a development milestone and recognition of deferred Huadong revenue.”
FILING10-K0001641489-26-000010cik 0001641489
“The increase in research and development expenses during this period of approximately $6.3 million, or 54.7%, was primarily driven by (i) higher spending on cadisegliatin of $5.4 million, due to increases clinical studies, (ii) an increase in indirect costs of $2.6 million primarily due to increases in payroll and bonus costs and a $1.0 million Novo license milestone payment, partially offset by (iii) a decrease of $1.7 million in other projects primarily related to the write off of an aged accrual.”
FILING10-K0001641489-26-000010cik 0001641489
Watchlist prices, news filtered to it, and its next report on your desk.
vTv Therapeutics Inc. has 4 disclosed suppliers and 5 disclosed customers. Each one is named in an SEC filing, either vTv Therapeutics Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
Prev close 30.42 · gapped above the open, then crossed back over prior close. High/low 30.91 at 10:00 am ET, 30.26 at 1:45 pm ET.
vTv Therapeutics Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
VTVT (vTv Therapeutics Inc.) has 4 disclosed suppliers and 5 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: NVO +0.24%, in industrials & materials.